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Abstract— Cancer refers to a group of diseases in which cells 
display uncontrolled growth. Chemotherapy options are usually 
conditioned by generating resistance which is explained in part by 
the intrinsic heterogeneity of the population in the tumor. Because 
the study of resistance requires biosensors able to report the 
response at the single cell level, we propose to use fluorescently 
labeled SL to estimate pathway dynamics at the single cell level 
and investigate its possible application as gemcitabine (GMZ) 
response sensor in pancreatic cancer by comparing the dynamics 
between GMZ resistant (Panc-1, MiaPaca-2) and sensitive 
(BxPC3) cell lines. We used imaging flow cytometry to extract 
multiple image features and classify cells using gaussian-mixture 
model (GMM) to generate response fingerprints upon known 
perturbations. The results suggest that GMZ inhibits the 
Sphingomyelin-Synthase of BxPC3. Also, we constructed and 
fitted a dynamical mathematical model to simulate these 
perturbations and formulate cell line models revealing a striking 
heterogeneity among them. Predictions of the model respect the 
effect of GMZ in the accumulation of ceramide in BxPC3 and 
glucosyl-ceramide in MiaPaca-4 were confirm experimentally. 
Altogether, these results indicate that fluorescent-SL analogues 
can be used as sensors of chemotherapy in pancreatic cancer and 
reveal pathway dynamics between different cell lines, and its 
potential usage for the development of in vitro chemosensitivy 
assays able to dissect pathway dynamics to overcome resistance. 
Keywords— Cancer; GMM; EDO; Sphingolipids. 
I. INTRODUCTION 
Cancer refers to a group of diseases in which cells display 
uncontrolled growth[1]. Chemotherapy options are usually 
conditioned by generating resistance which is explained in part 
by the intrinsic heterogeneity or robustness of the population in 
the tumor. Biological robustness is recognized as being a 
conserved organizing principle in biology including adaptation 
and tolerance, which are enabled by feedback controls, 
redundancy, modularity and structural stability. Because the use 
of biosensors for reporting the cellular response to 
chemotherapy could be achieved at single cell level, we suggest 
that the dynamic changes on the sphingolipid (SL) signaling 
pathway could be seen as a biosensor to predict chemotherapy 
response. This pathway is able to integrate different types of 
cellular stress signals and report dynamic phenotypes related to 
induction of cell death pathways [2].  
However, the cellular content of different sphingolipids is 
usually quantified at the whole-cell population level using mass 
spectrometry techniques. Therefore, we propose to use 
fluorescently labeled sphingolipid analogues to estimate the SL 
dynamics at the single cell level. In the present work we sought 
to investigate the possible application of SM-BOD (fluorescent-
sphingomyelin analogue) metabolism as a gemcitabine (GMZ) 
response sensor in pancreatic cancer cells, based on the 
comparison between GMZ resistant (Panc-1, MiaPaca-2) and 
sensitive cell lines (BxPC3), which difference was previously 
reported to be dependent on critical differences in the SL-
pathway [3]. To evaluate this we loaded cells with SM-BOD and 
assessed if they display dynamic changes in total cell 
fluorescence by imaging flow cytometry. In order to analyze the 
differential SM-BOD cellular metabolism related to resistance 
or sensitivity, we included known perturbations to the SL 
pathway in the presence and absence of GMZ. In addition, we 
extracted multiple image features of fluorescence texture and 
distribution to create multidimensional data at the single cell 
level and developed an algorithm based on gaussian-mixture 
models to study cellular heterogeneity and to generate a 
perturbation-response fingerprint for each cell line. 
In other hand, the SL signaling pathway is in fact complex, 
with multiple inputs and outputs, and is regulated spatially.  
Thus a systems level approach is necessary in order to 
deconvolve this pathway complexity to identify differences 
related to GMZ resistance. A dynamic mathematical model of 
SL-pathway was constructed to simulate the total fluorescent 
level changes upon perturbations. This model was fitted to the 
experimental, revealing striking differences in the chemotherapy 
response of the SL-pathway among cell lines.      
Altogether, the results indicated that fluorescent SL 
analogues can report changes related to resistance or sensitivity 
to chemotherapy in pancreatic cancer and provide information 
about pathway dynamics at the subpopulation level. This 
suggests a useful potential of this SL analogues as sensors of 
chemotherapy response for the development of in vitro 
chemosensitivy assays able to disentangle cancer heterogeneity. 
II. MATERIALS AND METHODS 
A. Cell viability and cell death assays  
In order to evaluate the chemosensibility of three pancreatic 
cancer cell lines to gemcitabine (GMZ), cell viability and cell 
death assays were stablished using a PrestoBlue assay and 
propidium iodide (PI) internalization assay, respectively. 
Different concentrations of GMZ were tested in the cell lines 
BxPC3 (sensible), MiaPaca-2  and Panc-1 (resistants), which 
were seeded in 96 well plates for 24h and incubated with 72h 
with the chemotherapy.  
 
B. Evaluation of the SM-BOD Metabolism 
A flow cytometry assay was performed for evaluating the 
cellular metabolism of SM-BOD as a potential sensor for the 
response to GMZ in the pancreatic cancer lines. Cells were 
seeded in 24 well plates, loaded with 0.25 μM of SM-BOD for 
30 min and treated with new medium containing the different 
inhibitors of the SL-pathway in presence/absent of GMZ (single 
or double perturbations): an sphingosine kinase inhibitor (SKI, 
20 μM ), glucosyl-ceramide synthase inhibitor (PDMP, 50 μM), 
neutral ceramidase inhibitor (NCI, D-erytro-MAPP, 50 μM), 
acidic ceramidase inhibitor (ACI, C-NMAPPD, 20 μM), 
ceramide kinase inhibitor (CKI, 50 μM ), a sphingomyelin-
synthase inhibitor (D609, 100 μM), an acid sphingomyelinase 
inhibitor (Desipramine, Des, 25 μM), a ceramide synthase 
inhibitor (FB1, fumonisin B1, 10 μM), a neutral ceramidase 
inhibitor (GW, GW4869, 5 μM) and a serine-palmitoyl CoA 
reductase (de novo synthesis) inhibitor (Myriocin, Myr, 200 
nM). After 24h of incubation, acquisition of images was done 
and they were analyzed using the IDEAS software. Several 
intensity, texture and morphological features were extracted 
from the cellular images for further analysis. All the 
measurements normalized in order to compare the initial values 
with the remaining fluorescence after 24h of exposition. 
 
C. GMM Algorithm for the analysis of cellular heterogeneity  
From the data obtained with the image analysis of flow 
cytometry assay, an unsupervised classification was established 
with Gaussian mixtures algorithm (GMM). This was done in 
order to create profiles of heterogeneity and identify those 
conditions that have a similar effect on the distribution of the 
fluorescence of SM-BOD at cellular level, and thus establish 
how the GMZ alters or is sensed in the sphingolipids pathway. 
 
D. Kinetics and predictions of the ODE mathematical model  
 In order to infer the transit of the SM-BOD in the 
sphingolipid pathway, we proceeded with construction of a 
 
Figure 1. (A) Cell viability and (B) cytotoxicity assays demonstrate that GMZ has a strong cytotoxic activity on the BxPC3 
sensible cell line but only a slight antiproliferative activity on the resistant cell lines Panc-1 and MiaPaca-2, being 100 uM the 
selected concentration that maximizes the difference. (C) An imaging flow cytometry assay was performed for evaluating the 
cellular metabolism of SM-BOD as a potential sensor for the response to GMZ in the pancreatic cancer lines. All the information 
of the measurements was extracted for analysis in the models. (D) Intensity distribution of the samples are plotted as histograms, 
mathematical model disturbance-based model, incorporating 
experimental data and literature information. Subsequently, the 
reaction kinetics was incorporated using ordinary differential 
equations (ODE) and based on the law of mass action, 
Michaelis-Menten kinetics or Hill coefficient. For parameters 
estimation, data of flow cytometry experiments were 
incorporated, adjusted separately and independently per cell line 
and with the Simmulated Anneling algorithm.  
 With the purpose of determine the predictions of the 
mathematical model with respect to changes in the composition 
of sphingolipids by cell line, simulations of presence / absence 
of GMZ in each model of each line were established, allowing 
inferring the relative amounts of sphingolipids. For the 
perturbation with GMZ, it was assumed that chemotherapy had 
the same effect that the inhibitor where it had been sensed. 
 
E. Validation assay 
The validation of changes in the composition of 
sphingolipids due to metabolism SM-BOD in the cell lines in 
presence/absence of GMZ was made using thin layer 
chromatography (TLC), comparing the BxPC3 cells with both 
the Panc1 and MiaPaca-2 cells. Briefly, the lipids were extracted 
using a mixture of isopropanol:water:ethyl-acetate and then the 
TLC was run. Pictures were taken under the excitation of a 
common UV transiluminator. It was possible to obtain a 
resolution able to separate the fluorescent SL-species of four 
standards in the order according to their migration: 
sphingomyelin-BODIPY, glucosyl-ceramide BODIPY, 
BODIPY-fatty acid and ceramide-BODIPY.  
III. RESULTS 
A. Response to GMZ can be sensed by changes in fluorescent 
sphingolipid metabolism in pancreatic cancer cell lines 
 In order to establish an optimal GMZ concentration for the 
experimental conditions, we compared the sensitivity of BxPC3, 
Panc1 and MiaPaca-2 cells to different concentrations of GMZ. 
For all cell lines, no significant increase in cell death was 
observed during the first 48h (not shown). However, the BxPC3 
cells were drastically impacted after 72h. The BxPC3 cells 
showed a significantly reduced viability to 20-30% of the 
control when incubated with GMZ concentrations as low as 0.1 
μM (Figure 1A). This decrease in viability was accompanied by 
a dose-dependent increase in PI labeling, reaching a maximum 
at a concentration of 100 μM, indicating that the reduced BxPC3 
cell number is related to cell death (Figure 1B). On the other 
hand, both Panc1 and MiaPaca-2 cell lines showed only a dose-
dependent reduction in cell viability to a minimum of 65% at 
100 μM, without a significant increase in PI staining, suggesting 
that GMZ induces only an antiproliferative effect on those 
resistant cell lines. Based on these results, we chose a 
concentration of 100 μM of GMZ (referred as GMZ hereafter) 
to maximize the effect, if any, of GMZ on both resistant cell 
lines (Panc1 and MiaPaca-2) compared to the sensitive BxPC3 
cell line. 
 
Figure 2. Gaussian Mixure Model. (A) The implementation of a GMM sets a script in MATLAB with three general steps: (i) 
data from all conditions were combined to form a total population to explore the whole range of possible disturbances, (ii) the 
number of subpopulations of cells that maintained normal distribution in the entire space of possibilities and n-dimensions (the 
number of features) were identified, and (iii) each cell was reallocated to its corresponding disturbance assay and a 
classification was performed with the original cells to divide between subpopulations and then a MANOVA test to determine 
if that classification identifies subpopulations that differ significantly from each other. The algorithm defines the optimal 
iteration as that maximum number of Gaussians subpopulations able to identify subpopulations with statistically significant 
difference (B). Subpopulations in the whole-space of possibilities are shown in (C). 
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To evaluate whether the cellular metabolism of SM-BOD 
has potential as a sensor for the response to chemotherapy 
(GMZ) in pancreatic cancer, we loaded cells with SM-BOD 
and assessed if they display changes in the remaining cellular 
fluorescence after 24h compared to control. Cells were seeded 
and exposed to SM-BOD for 30 min, and after 24h incubation, 
the cells were analyzed by imaging in the flow cytometer. The 
acquired images were analyzed according to intensity, texture 
and morphological features (Figure 1C). The distributions of 
cellular fluorescence intensities (total pixels) showed 
differences between the sensitive and resistant cell lines 
(Figure 1D) after 24h.  
 
B. The cellular effects of GMZ can be sensed in the SL-
pathway 
A GMM was performed in order to establish a 
heterogeneity profile per each perturbation as a fingerprint 
(algorithm details in Figure 2-A). For this propose, the data of 
cell features in each perturbation assay were joined for 
identifying the maximum number of subpopulations with 
normal distribution and evaluated with a MANOVA test. 
Iteratively, it was concluded that the maximum number of 
subpopulations was 10, as it is shown in Figure 2-B. The whole 
space of possibilities is presented in Figure 2-C where is 
possible to identify the 10 gaussian subpopulations. In the 
algorithm, the fingerprint in Figure 3 (left) was obtained from 
reclassify all the cells into their original assay and then 
determinate the frequency of each subpopulation in the 
perturbation. Finally, the clustering analysis to evaluate the 
similarities of the heterogeneity profile was made with a 
statistic significant of 0.05 and Euler distance, where is 
possible to identify that D609 and GMZ have similar profile, 
suggesting that modification of the sphingolipids pathway of 
both remains close and concluding that GMZ can be sensed in 
the step where D609 acts, the Sphingomyelin-Synthase (Figure 
3, right). 
 
C. Predictions of the ODE model about the composition of SL 
in BxPC3 and MiaPaca-2 with GMZ treatment can be 
verified experimentally  
The topological model of the pathway of sphingolipids 
based on available data and literature is presented in Figure 4-
A. The topology was made with iterative changes based on 
minimize the adjustment function. The model starts with an 
input of SM-BOD (sphingomyelin-BODIPY) assumed 100% at 
time 0, and which is metabolized by different enzymes and 
transformed into various species that may or may not preserve 
the fluorescent species.. The parameter estimation was 
performed with each cell line and data of the perturbations were 
incorporated into each model in both presence/ absence of 
GMZ. Figure 4-B presents the comparison of total fluorescence 
of experimental and simulated data for cell lines in the absence 
of chemotherapy, which shows that the model does fit the 
experimental data (with an acceptable error less than one 
standard deviation of the experiments). Furthermore, it can be 
seen that the total fluorescence (and therefore the composition 
sphingolipid) in each cell line is different. To infer the 
composition of sphingolipids in each case, simulations in the 
presence / absence of GMZ, were conducted as it is shown in 
Figure 4-C, revealing a significant increase of ceramide in 
BxPC3 and glucosyl-ceramide in MiaPaca-2 cell lines under 
exposition to GMZ, which are set as hypothesis of the 
mathematical model. 
 
In order to validate the changes obtained from the 
mathematical model of different fluorescence  intensities 
between sensitive and resistant cell lines in SL-sensor 
metabolism upon GMZ, we studied the fluorescent-SL 
composition of cell pellets using thin layer chromatography 
(TLC) comparing the BxPC3 cells with both the Panc1 and 
MiaPaca-2 cells. The BxPC3 cells showed a striking increase 
of ceramide-BODIPY and a slight increase in BODIPY-labeled 
fatty acid upon GMZ treatment compared to control. On the 
other hand, Panc-1 cells showed no significant differences in 
lipid composition upon treatment, whereas MiaPaca-2 cells 
showed a shifted band closed to the glucosyl-ceramide-
BODIPY. This indicates that GMZ alters the SL-metabolism 
deviating it towards the production of mainly ceramide in the 
GMZ sensitive BxPC3 cells. In contrast, GMZ has no effect on 
the SL metabolism in Panc-1 cells.  
 
 
Figure 3. Clustering analysis. Using the GMM, data of each 
disturbance (inhibitor with/without GMZ) and the frequency of 
each subpopulation define a pattern of heterogeneity 
(fingerprint) related to each disturbance. With the fingerprint 
information, a clustering analysis to associate the various 
disturbances each other was made. Clustering shows that GMZ 
can be sensed as the D609 inhibitor.  
 
Interestingly, GMZ produces changes in the SL 
metabolism in MiaPaca-2 cells which are reflected only as a 
slight shift in fluorescence intensity compared to control 
(Figure 1D), although they are not related to cell death. 
IV. DISCUSSION 
Because the role of sphingolipids in cell signaling and the 
mechanisms of death/ survival, cancer approach with the use of 
sphingolipids pathway provides the ability to seek new 
alternatives for customization of therapy. In our study, the 
characterization of the cell lines according to their sensitivity to 
GMZ was described with viability and cytotoxicity assays, 
confirming the sensitivity of BxPC3 and resistance of Panc-1 
and MiaPaca-2. In addition, changes in the composition of 
sphingolipids, in the presence and absence both of GMZ, was 
showed with the SM-BOD and total fluorescence values. 
In order to gain insight into the effect of GMZ on the SL 
metabolism of each cell line, we designed a strategy of single 
and double perturbations to identify interactions between GMZ 
and known perturbations to the SL pathway. The interactions of 
GMZ with the SL-pathway perturbations also differ between the 
cell lines which suggest the presence of underlying cell line-
specific differences in the SL-metabolism. Furthermore, this 
response profiles did not seem homogeneous even within the 
cells of the same cell line. This feature was considered in a study 
conducted in 2008, which it showed the heterogeneity role with 
data of biosensors in a GMM model. In this case, analysis of 
GMM was used to characterize cellular phenotypes in drug 
response, allowing to distinguish different classes of drugs based 
 
Figure 4. ODE mathematical model of SL. (A) Topology of the model shows the transit of the SM-BOD in different 
compartments. Some reactions can ends in a loss of the fluorescence specie of the SL-analogue and consequently a reduction of 
the total fluorescence. The parameters estimation was done with the single or double perturbation data, where it is possible to 
appreciate the fitted model and a cell line specificity of the total fluorescence in each condition (B, only for single perturbation). 
Predictions of the model were run for both control and GMZ conditions, showing a different distribution of SL in all the cell lines 
(C). Validation of those changes was verified experimentally with a TLC assay, showing accumulation of ceramide(Cer) in the 
BxPC3 and glucosyl-ceramide (GC) in MiaPaca-2 in presence of GMZ.  
on its mechanism of action and revealing biological differences 
in populations selected by the GMM [4].  
In our case, a model of GMM was performed with several 
morphological, intensity and texture features which were 
extracted from the cellular images of the flow cytometry assay, 
showing the differences in the subpopulation composition as a 
fingerprint. According to the clustering analysis of the profiles 
in each condition of our study, the GMM shows that D609 and 
GMZ have similar profile, suggesting that GMZ can be sensed 
in the step where D609 acts, the Sphingomyelin-Synthase, 
which has not been previously reported. In fact, there are few 
reports in the literature about how chemotherapies can be sensed 
in the sphingolipid pathway. Doxorubicin and etoposide for 
example affect the function of sphingosine kinase [5]. 
In other hand and using a system biology approach, an ODE 
model was fitted with the fluorescence data of the perturbations, 
including the effect of the chemotherapeutic drug GMZ in the 
Sphingomyelin-Synthase. The proposed model of sphingolipids 
simulated the transit of the SM-BOD fluorescent species for the 
cell. Since the proposed model was based on disturbances and 
ordinary differential equations, it was possible to describe the 
effect or impact of the GMZ in specific SL (by inference) after 
it has reached a state of equilibrium, which served to generate 
hypothesis. Predictions of the mathematical model reveal an 
accumulation of ceramide in sensible cell line BxPC3 in 
presence of GMZ, which were shown with the experiment result 
with the TLC assay.  
In this regard, sphingolipids play a key role in activation of 
death mechanisms, being ceramide one of the most 
characterized species, which is involved in apoptotic, 
necroptosis and autophagy death mechanisms and occurs in 
various cellular compartments[6]. For the simulation of Panc-1 
cell line, the simulations show some discrete changes in 
ceramide and glucosyl-ceramide, which could not being verified 
with the TLC assay, however, in the case of MiaPaca-2, the 
accumulation of glucosyl-ceramide was predicted by the 
mathematical model and clearly shown in the validation assay.  
Several reports have shown a relationship between the 
activity of the glucosyl ceramide synthase (GCS) and 
chemoresistance, in which multiple mechanisms may be 
involved, including decreased the concentration of biologically 
active ceramide [6]. Giussani and coworkers showed that 
glucosylceramide protects glioblastoma cells against autophagic 
and apoptotic by Temozolomide and Paclitaxel induced death, 
and the concomitant use of inhibitors of glucosylceramide 
synthase revert that resistance to enhance the cytotoxic effects 
of these drugs [7]. These two reports are consistent with 
experimental data MiaPaca-2 cell line. 
However, a 2003 study in which evaluated Doxorubicin, 
Paclitaxel, Cytosine arabinoside, and analogs of ceramide of 
short chain did not generate difference in sensitivity of a line of 
murine melanoma by inhibiting GCS or increase their activity 
[8]. These findings suggest that the regulation of GCS in 
chemoresistance depends on the type of cell that can act through 
different mechanisms, which could explain the few changes seen 
for the Panc-1 cell line. 
In general, the usage of double perturbation studies lets to 
understand the interactions of single components and systems 
level properties, which is wealthy for understanding the biology 
of SL in the cell cancer in this case. Taken together, these results 
demonstrate the potential of the SL-sensor to report changes 
upon perturbations in SL-metabolism at the population level 
induced by the chemotherapeutic drug GMZ, which affect the 
Sphingomyelin-Synthase activity. They also indicate that 
although GMZ does not induce cell death in resistant cell lines, 
they in fact respond to GMZ by changes in their SL-metabolism 
which are more evident in the presence of specific perturbations. 
Cell specific responses could be related with resistance and 
therefore the understanding of these responses has a potential for 
the design of strategies to revert drug resistance. 
ACKNOWLEDGMENT  
We thank the valuable contributions of Dr. Stefan Legewie and 
Professor Roland Eils. 
 
REFERENCES 
[1] A. Z. Fernandis y M. R. Wenk, «Lipid-based biomarkers for 
cancer.», J. Chromatogr. B. Analyt. Technol. Biomed. Life 
Sci., vol. 877, n.o 26, pp. 2830-5, sep. 2009. 
[2] T. S. Tirodkar y C. Voelkel-Johnson, «Sphingolipids in 
apoptosis.», Exp. Oncol., vol. 34, n.o 3, pp. 231-42, oct. 2012. 
[3] J. Guillermet-Guibert, L. Davenne, D. Pchejetski, N. Saint-
Laurent, L. Brizuela, C. Guilbeau-Frugier, M.-B. Delisle, O. 
Cuvillier, C. Susini, y C. Bousquet, «Targeting the 
sphingolipid metabolism to defeat pancreatic cancer cell 
resistance to the chemotherapeutic gemcitabine drug.», Mol. 
Cancer Ther., vol. 8, n.o 4, pp. 809-20, abr. 2009. 
[4] M. D. Slack, E. D. Martinez, L. F. Wu, y S. J. Altschuler, 
«Characterizing heterogeneous cellular responses to 
perturbations.», Proc. Natl. Acad. Sci. U. S. A., vol. 105, n.o 
49, pp. 19306-11, dic. 2008. 
[5] E. Bonhoure, A. Lauret, D. J. Barnes, C. Martin, B. 
Malavaud, T. Kohama, J. V Melo, y O. Cuvillier, 
«Sphingosine kinase-1 is a downstream regulator of imatinib-
induced apoptosis in chronic myeloid leukemia cells.», 
Leukemia, vol. 22, n.o 5, pp. 971-9, may 2008. 
[6] L. Chai, R. P. McLaren, A. Byrne, W.-L. Chuang, Y. Huang, 
M. R. Dufault, J. Pacheco, S. Madhiwalla, X. Zhang, M. 
Zhang, B. a Teicher, K. Carter, S. H. Cheng, J. P. Leonard, Y. 
Xiang, M. Vasconcelles, M. a Goldberg, D. P. Copeland, K. 
W. Klinger, J. Lillie, S. L. Madden, y Y. a Jiang, «The 
chemosensitizing activity of inhibitors of glucosylceramide 
synthase is mediated primarily through modulation of P-gp 
function.», Int. J. Oncol., vol. 38, n.o 3, pp. 701-11, mar. 2011. 
[7] P. Giussani, R. Bassi, V. Anelli, L. Brioschi, F. De Zen, E. 
Riccitelli, M. Caroli, R. Campanella, S. M. Gaini, P. Viani, y 
L. Riboni, «Glucosylceramide Synthase Protects 
Glioblastoma Cells Against Autophagic and Apoptotic Death 
Induced by Temozolomide and Paclitaxel», Cancer Invest., 
vol. 30, n.o 1, pp. 27-37, ene. 2012. 
[8] R. J. Veldman, A. Mita, O. Cuvillier, V. Garcia, K. Klappe, 
J. A. Medin, J. D. Campbell, S. Carpentier, J. W. Kok, y T. 
Levade, «The absence of functional glucosylceramide 
synthase does not sensitize melanoma cells for anticancer 
drugs.», FASEB J., vol. 17, n.o 9, pp. 1144-6, jun. 2003.
 
